Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major apple allergen Mal d 1 is a 17.5 kDa pathogenesis-related class 10 (PR-10) protein recognized as the predominant allergen responsible for apple (Malus domestica) allergies, particularly in Europe and Northern America[1][2][3]. It shares high sequence and structural similarity to the major birch pollen allergen Bet v 1, leading to frequent immunological cross-reactivity: individuals sensitized to birch pollen often experience allergic reactions upon consuming apples due to the structural similarity triggering IgE-mediated responses[1][2][3]. Mal d 1 is present in both the peel and pulp of apples (higher in the peel) and exists as multiple isoallergens encoded by a large gene family[3]. It is a cytosolic, heat- and protease-labile protein that adopts a canonical PR-10 fold, consisting of a large hydrophobic cavity formed by a seven-stranded β-sheet and three α-helices[1][2]. Biologically, Mal d 1 has a role in plant defense against biotic and abiotic stresses, but in human health, its main relevance is as the molecular trigger of apple-induced food allergies, including oral allergy syndrome and, less commonly, systemic allergic reactions[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major apple allergen Mal d 1 (Mal d 1).